Kornimate/medical-research-clean huggingface dataset:
artificial intelligence in dental implant planning

Conditions: Edentulous Alveolar Ridge; Edentulous Mouth; Tooth Loss

Summary: artificial intelligence (ai) is revolutionizing the dentistry, offering new opportunities to improve the precision and efficiency of implantology. this study aims to evaluate the current evidence on the use of ai in implant planning assessment

the analysis was conducted through electronic search engines, using a combination of relevant keywords, including "artificial intelligence implantology," "ai implant planning," "ai dental implant," and "implantology artificial intelligence." selected articles will carefully re-viewed to identify studies reporting data on the effectiveness of ai in implant planning.

Eligibility criteria:
inclusion criteria: * patients who underwent 3d or 2d radiological examinations for implant-prosthetic rehabilitation

Keywords: artificial intelligence in implantology ai in dental implantology machine learning in dental implantology deep learning in implant dentistry robotics in dental implantology ai-based implant planning
the phosphodiesterase 5 inhibitor sildenafil as an adjunct to antidepressants in major depressive disorder patients

Conditions: Major Depressive Disorder

Summary: antidepressant-like effects of sildenafil to its ability to modulate transduction pathways responsible for neuroplasticity. treatment with sildenafil was shown to be pkg-dependent and lead to increased expression of cgmp, pcreb, bdnf and vgf in the hippocampus and prefrontal cortex (pfc), brain areas relevant to mood disorders pathophysiology. sildenafil produces antidepressant-like effects by inhibiting oxidative stress in the hippocampus and by decreasing the levels of il-1β in the hippocampus and striatum.


Eligibility criteria:
inclusion criteria: * eighty adult outpatients with the diagnostic and statistical manual of mental disorders-iv (dsm-iv) diagnosis of mdd based on a mini neuropsychiatric interview (mini) (american psychiatric association., 2000; sheehan et al., 1998), without psychotic features and a total 17 item ham-d score of at least 18 with item 1 (depressed mood) scored 2 or greater were eligible (hamilton, 1960). * patients were requested to be free of all the psychotropic and anti-inflammatory medications for at least 4 weeks before participating in the study. exclusion criteria: * patients with bipolar i or bipolar ii disorder * patients with personality disorders * patients with eating disorders * patients with substance dependence or abuse * patients with concurrent active medical condition * patients with history of seizures * patients with history of receiving electroconvulsive therapy (ect) * patients with inflammatory disorders * patients with allergy or contraindications to the used medications * patients with finally pregnant or lactating females * cardiovascular disorders * severe renal impairment: creatinine clearance of ≤ 25 ml/min * moderate or severe hepatic impairment
validation of user needs of the point digit with partial hand amputees

Conditions: Amputation; Traumatic, Hand

Summary: the objective of the device feasibility study will be to validate the user needs of the point digit system. this study will be a single group intervention model where one group of 5 partial hand amputees will be asked to perform several tasks. successful completion of a task results in a fulfilled user need. failure to complete a task results in an unfulfilled user need.


Eligibility criteria:
inclusion criteria: * partial hand amputees with absence of index and/or middle fingers and presence of thumb. additional finger loss is acceptable if all other criterion are met. * fluent in english * individuals aged 18 or greater exclusion criteria: * significant cognitive deficits as determined upon clinical evaluation * significant neurological deficits as determined upon clinical evaluation * significant physical deficits of the residual limb impacting full participation in the study as determined upon clinical evaluation * uncontrolled pain or phantom pain impacting full participation in the study as determined upon occupational therapist evaluation * serious uncontrolled medical problems as judged by the project therapist.
evaluation of infigratinib in patients with locally advanced or metastatic gastric cancer or gej adenocarcinoma

Conditions: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma

Summary: this is a multicenter, open-label, single arm phase ii study to evaluate the efficacy and safety of infigratinib in patients with locally advanced or metastatic gc or gej patient with fgfr2 gene amplification, who have failed at least 2 lines of previous standard systemic treatment .


Eligibility criteria:
inclusion criteria: * 18 years and older * histologically or cytologically confirmed locally advanced or metastatic gastric adenocarcinoma, or gastroesophageal junction adenocarcinoma. * failed at least 2 lines of prior systemic therapy * willing to undergo tumor biopsy or provide ffpe samples for central lab testing. * at least one measurable tumor lesion by recist v1.1 * eastern cooperative oncology group (ecog) performance status of 0 or 1. * life expectancy ≥3 months. * willing to participate in this study and sign informed consent form, able to read and understand the study, follow the procedures. exclusion criteria: * history of other primary malignancies within 3 years except adequately treated in situ carcinoma of the cervix or non-melanoma carcinoma of the skin or any other curatively treated malignancy that is not expected to require treatment for recurrence during the study. * previous or current treatment of a mitogen-activated protein kinase (mapk-mek) or selective fgfr inhibitor. * any known hypersensitivity to infigratinib or its excipients. * history and/or current evidence of extensive tissue calcification. * current evidence of endocrine alterations of calcium/phosphate homeostasis. * have impairment of gastrointestinal (gi) function or gi disease that may significantly alter the absorption of oral infigratinib (such as, ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection).14. laboratory abnormality as defined in protocol. * considered unsuitable to participate in the study by investigator

Keywords: gastric cancer gastroesophageal junction adenocarcinoma fgfr2
efficacy, safety and tolerability of the co-administration of nva237 plus indacaterol once daily versus indacaterol once daily in patients with moderate to severe chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: this study assessed the efficacy, safety and tolerability of the co-administration of nva237 plus indacaterol taken once daily versus indacaterol taken once daily in patients with moderate to severe chronic obstructive pulmonary disease.


Eligibility criteria:
inclusion criteria: * patients with moderate to severe stable chronic obstructive lung disease (copd) stage ii or stage iii according to global initiative for chronic obstructive lung disease (gold) guidelines. * patients with a post-bronchodilator forced expiratory volume in 1 second (fev1) ≥ 30 % and/or \<80 % of the predicted normal, and a post-bronchodilator fev1/forced vital capacity (fvc) \< 0.70 at screening. * current or ex-smokers who have a smoking history of at least 10 pack years * symptomatic patients according to daily diary data. exclusion criteria: * pregnant or nursing (lactating) women. * women of child-bearing potential unless using adequate contraception. * patients with type i or uncontrolled type ii diabetes. * patients with a history of long time interval between start of q wave and end of t wave in the heart's electrical cycle (qt) syndrome or whose qt corrected for heart rate (qtc) measured at screening (visit 2) (fridericia's method) is prolonged * patients with paroxysmal (e.g. intermittent) atrial fibrillation * patients who have a clinically significant electrocardiogram (ecg) or laboratory abnormality at screening (visit 2) other protocol-defined inclusion/exclusion criteria may apply.

Keywords: indacaterol glycopyrronium bromide copd bronchodilation
success of lesion sterilization and tissue repair therapy

Conditions: Primary Teeth; Pulp Necrosis; Pulpitis - Irreversible

Summary: this study aimed to assess the clinical and radiographic success of lesion sterilization and tissue repair (lstr) therapy with different antibiotic combinations, focusing on evaluating whether the alternative combination of clindamycin instead of minocycline is as effective as the standard 3mix-mp formulation.

all the clinical procedures were carried out by one clinician with 2 years of clinical experience in pediatric dentistry under rubber dam isolation and local anesthesia via mandibular nerve block. (maxicaine fort ampoule, vem, turkiye). after the removal of carious tissues, an endodontic cavity was prepared, and infected coronal pulp tissue was removed up to the canal orifices via a sterile round steel bur. a sterile round steel bur was then used to prepare a medication cavity 2 mm deep and 1 mm wide. the root canals were not instrumented, and only the access cavity was irrigated with a 2.5% naocl solution. in cases where hemostasis could not be achieved, a sterile cotton pellet soaked in 5% naocl was placed in the pulp chamber and left for 1 minute. once hemostasis was achieved, the endodontic cavity was dried using a sterile, dry cotton pellet. pastes were then applied to the medication cavity and covered with a glass ionomer cement (nova glass ii f, imicryl, turkiye) and a stainless steel crown (kids crown, shinhung, seoul, korea) at the same visit. clinical and radiographic evaluations were performed at 1, 3, 6, 9, and 12 months. during follow-up, the teeth were assessed on the basis of the following clinical criteria: pain, dentoalveolar abscess and/or fistula, and tooth loss. the radiographic criterion was periapical radiolucency.

Eligibility criteria:
inclusion criteria: * spontaneous pain * pain on percussion * the presence of abnormal or pathological mobility * the presence of a sinus tract or dentoalveolar abscess * widening of the periodontal ligament * periradicular radiolucency * evidence of external and/or internal resorption. exclusion criteria: * who required infective endocarditis prophylaxis * who had used antibiotics in the two weeks prior to treatment * i̇ndividuals allergic to the medications used in the study * teeth with pulp floor perforation * advanced internal and/or external root resorption * root canal obliteration * excessive bone loss in the furcation area involving the permanent tooth follicle * teeth with severe coronal destruction, nonrestorable.

Keywords: lesion sterilization and tissue repair antibiotics
low-frequency pulsed electromagnetic fields (elf-mf) as treatment for acute ischemic stroke

Conditions: Stroke, Acute; Ischemic Stroke

Summary: the main purpose of this multicentric, prospective, randomized, placebo-controlled, double-blind study is the validation of pulsed elf-mf stimulation as non-invasive and safe tool to promote recovery in acute ischemic stroke patients. 124 patients with acute ischemic stroke will be recruited and randomly assigned to real or sham group. patients will be stimulated with pulsed elf-mf (75 hz, 1,8 mt), for 120 min daily, for 5 consecutive days, starting within 48 hours from the onset of stroke. the primary outcome will consist of reduction of the expected infarct growth at mr measured in the subacute and chronic phase. secondary outcomes will explore clinical effectiveness, safety and tolerability of pulsed elf-mf in acute ischemic stroke.


Eligibility criteria:
inclusion criteria: * first onset, mono-hemispheric ischemic stroke in the middle cerebral artery territory; * onset of symptoms within 48 hours; * national institutes of health stroke scale (nihss) score between 4 and 25; * signed written informed consent. exclusion criteria: * acute intracranial hemorrhage; * previous ischemic or hemorrhagic stroke; * lacunar stroke, defined as not involving the cortex and \< 2.0 cm if measured on mri diffusion-weighted images; * contraindications to transcranial magnetic stimulation such as implanted metallic parts of implanted electronic devices or other metal in body; * historical modified rankin scale (mrs) \>1; * other serious or complex disease that may confound treatment assessment; * women known to be pregnant, lactating or having a positive or indeterminate pregnancy test; * current participation in another study.

Keywords: acute ischemic stroke neuroprotection extremely low frequency magnetic fields
cesarean section scar niche: the impact on art outcome

Conditions: Cesarean Section; ART

Summary: to evaluate the impact of the presence of cesarean section niche and its characteristics on the outcome of art cycles.

the incidence of cesarean section (cs) is increasing worldwide, with a corresponding increase in its associated complications. the well-known complications are infection, hemorrhage, and increased risk of obstetric complications in subsequent pregnancies, like morbidly adherent placenta, cs scar pregnancies and uterine rupture. in addition, some studies emphasize the effect of cesarean sections on reduced fertility. a meta-analysis reported that a caesarean section reduces the probability of subsequent pregnancy by 10%, compared with a previous vaginal delivery. the cesarean section niche is defined as an indentation of the uterine myometrium of at least 2 mm at the site of the caesarean scar. the most common symptom of niche is abnormal uterine bleeding. meanwhile, other symptoms include dysmenorrhea, chronic pelvic pain, dyspareunia, and sub-fertility/infertility. the detection of a cesarean section niche depends on the operator and the diagnostic method used. this can be 2d, 3d transvaginal sonography, sonohysterography or hysteroscopy. regarding art, the presence of cs niche was reported to reduce the chances of embryo implantation, and increase the rate of spontaneous miscarriages, especially if the implantation is close to it or in the niche. the presence of a niche may increase the difficulty of embryo transfer procedure, clinicians need to be aware of its presence and the transfer should be done under ultrasound guidance to ensure the catheter bypasses the niche and enters the uterine cavity. still the impact of c.s niche and its characteristics on outcome of art is not clear.

Eligibility criteria:
inclusion criteria: 1. aged from 18 - 37 years old. 2. having a history of one or more previous cs with ultrasonographic visible cesarean section niche (for the group with cs scar niche), which is regarding to european niche taskforce is an indentation of the uterine myometrium of at least 2 mm at the site of the cs scar (jordans et al., 2019). 3. a normal uterus with no anomalies or pathologies. 4. at least one good-quality embryo available for transfer. exclusion criteria: 1. younger than 18 or older than 37 years old. 2. congenital uterine abnormality or pathology. 3. presence of a hydrosalpinx. 4. icsi cycles with tese samples.

Keywords: cesarean section niche art
home-based transcranial static magnetic field stimulation (tsms) of the supplementary motor area in parkinson's disease

Conditions: Parkinson's Disease

Summary: this is a pilot open study to test the hypothesis that home-based transcranial static magnetic field stimulation (tsms) of the supplementary motor area is safe and feasible to modulate corticostriatal activity in patients with parkinson's disease.


Eligibility criteria:
inclusion criteria: * idiopathic parkinson's disease (brain bank criteria) * optimal clinical response to dopaminergic medication (\>30% mds-updrs-iii improvement) exclusion criteria: * mri-incompatible metal objects in the body (e.g. cardiac pacemakers) * presence of levodopa-induced dyskinesias * other main neuropsychiatric co-morbidity
shockwave therapy in lower limb intermittent calf claudication

Conditions: Peripheral Vascular Disease

Summary: peripheral arterial disease is a common condition affecting approximately 64% of 56-77 year olds. this condition restricts bloody supply to calf muscles. pain occurs after walking a short distance and increases in intensity until the person stops, where the pain then gradually subsides. it can be limiting or occasionally debilitating and has been shown to have considerable deleterious effects of patients quality of life. shock wave therapy has been shown to promote new blood vessel formation and improved healing amongst other findings. this study aims to identify whether shock wave therapy that is applied to the calf muscles causes such an effect to improve the blood supply to the calf muscles, reduce pain, improve walking ability and quality of life.

this study aims to compare the effects of extracorporeal shockwave therapy (eswt) to placebo with use of a sham control group on walking distances in subjects with lower limb intermittent calf claudication. extracorporeal shockwave therapy will be applied using the piezowave2 shockwave system. all applications will be in adherence to the manufacturer's instructions and provided by trained staff. the device will be targeted at the gastrocnemius muscles of the affected lower leg for several minutes at each treatment session. participants in control group will undergo the identical process as if treatment were being given but with the shockwaves not being administered and a sham device alternatively used. participants will have several assessments prior to and after the shockwave treatment in order to quantify the effect. assessments will include maximum walking distance (mwd), claudication distance (cd) and quality of life questionnaires.

Eligibility criteria:
inclusion criteria: * patients with unilateral or bilateral intermittent calf claudication (stable for the last 3 months). * able to give written informed consent to participate in the study * age \> 18 * able to adhere to protocol and attend all follow up appointments * currently receiving "best medical therapy" - anti-platelet and statin medication exclusion criteria: * current malignancy * allergies or intolerances of either anti-platelet medication or statin therapy * pregnancy (pregnancy test performed at screening if necessary) * metal implant near to treatment area * anti-coagulation medication (i.e. warfarin)
a crossover study to assess the bioequivalence of hydrocodone bitartrate extended-release tablet

Conditions: Pain

Summary: the primary objective of this study is to assess the bioequivalence of two 30-mg hydrocodone bitartrate extended-release tablets and one 60-mg hydrocodone bitartrate extended-release tablet.


Eligibility criteria:
inclusion criteria: * written informed consent is obtained. * the subject can read, speak, and write in english. * the subject is a man or woman 18 through 45 years of age, with a body mass index (bmi) of 20.0 to 30.0 kg/m2, inclusive. * the subject is in good health as determined by medical and psychiatric history, physical examination, ecg, serum chemistry, hematology, urinalysis, and serology. * women must be surgically sterile, 2 years postmenopausal, or, if of child-bearing potential, be using an acceptable method of contraception, and agree to continued use of this method for the duration of the study and for 30 days after discontinuation of study drug. acceptable methods of contraception include abstinence or an intrauterine device (known to have a failure rate of less than 1% per year). * the subject has a negative alcohol test and urine drug screen (uds). * the subject must be willing and able to comply with study restrictions and to remain at the study center for the required duration of each study drug period during the study. exclusion criteria: * the subject has any clinically significant uncontrolled medical conditions (treated or untreated). * the subject has a clinically significant deviation from normal in ecg or physical examination findings, as determined by the investigator or the medical monitor. * the subject has habitually consumed, within the past 2 years, more than 21 units of alcohol per week, or has a history of alcohol, narcotic, or any other substance abuse as defined by the diagnostic and statistical manual of mental disorder, fourth edition, text revision (dsm-iv-tr, american psychiatric association 2000). note: a unit of alcohol is equal to 1 ounce of hard liquor, 5 ounces of wine, or 8 ounces of beer. * the subject is a pregnant or lactating woman. (any women becoming pregnant during the study will be withdrawn from the study.) * the subject has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal (gi) surgery; a history of appendectomy is allowed). * the subject has received any investigational drug within 30 days or 5 half-lives (whichever is longer) before the 1st dose of study drug, or in the case of a new chemical entity, 3 months or 5 half-lives (whichever is longer) before the 1st dose of study drug. * the subject has a known sensitivity or idiosyncratic reaction to hydrocodone or hydromorphone, their related compounds, or to any metabolites, or naltrexone, or any compound listed as being present in a study formulation. * other exclusion criteria apply.

Keywords: bioequivalence, hydrocodone bitartrate extended-release tablets
efficacy of emf bci based device on acute stroke

Conditions: Acute Stroke

Summary: the study tests the efficacy of a non-invasive device with low intensity electromagnetic field dedicated treatment to enhance the recovery of stroke patients impaired hand motor function

the study investigates the effect of bci based stimulation device on upper limb motor function of acute stroke patients. the bq device (brainq technologies ltd., israel), a brain computer interface based stimulation device, uses machine learning tools to identify high resolution spectral patterns associated with motor functions in eeg measurements of healthy/non healthy subjects. these patterns are then translated into a tailored frequency dependent low intensity, non-invasive electro-magnetic treatment protocol.

Eligibility criteria:
inclusion criteria: 1. diagnosis of 1st ever ischemic stroke confirmed by imaging or 1st recurrent ischemic stroke with no previous neurological impairment in the same limb before current stroke happened 2. 72h to 15 days from stroke onset or 21 days from stroke onset in case the patient was still unstable at day 15 from stroke onset). 3. medically stable patients 4. age: \> 18, \<80 years, and independent in their daily activities before the stroke 5. right dominant hand 6. fm \>10, \<45 of upper tested limb. 7. able to sit in a chair for 70 consecutive minutes and follow three verbal instructions: * bring your healthy arm to the level of your shoulder * pick up this pen with your healthy hand. * put your healthy hand on your waist 8. able to understand the information provided and provide informed consent exclusion criteria 1. contraindication for performing mri scanning 2. history of recent epileptic seizures or epilepsy and/or currently taking medication that are known to lower the seizure threshold 3. patients with an acute problem such as active infection at the time of recruitment for research 4. previous disease of the central nervous system 5. damage to the joints, bones and muscles causing restriction of movement of the upper limb being tested 6. patients known to suffer from some peripheral nerve damage of the upper limb that being tested 7. pregnant women and women who have the ability to become pregnant unless they are on an acceptable method of contraception during the study. 8. alcoholism or drug addiction as defined by dsm-iv within last 5 years

Keywords: bci bq motor function acute stroke emf